Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Ramucirumab versus placebo as second-line treatment in pa... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
0
Authors
Andrew Zhu
25 more
Andrew Zhu
•
Ronnie Poon
23 more
•
Masatoshi Kudo
Published
June 19, 2015
Paper
Conversation
0
Reviews
0
Bounties
0
Abstract
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
The Lancet Oncology
Topics
Medicine
Cancer Oncology
Pathology
Internal Medicine
Surgery
Show all topics
DOI
10.1016/s1470-2045(15)00050-9
